{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:28:46Z","timestamp":1779373726159,"version":"3.53.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Mycophenolate mofetil is widely used in liver transplantation but poses dosing challenges owing to the narrow therapeutic window and high pharmacokinetic variability of its active moiety, mycophenolic acid (MPA). Overexposure increases the risk of adverse effects, whereas underexposure increases the risk of rejection and graft loss. The ImmunoSuppressant Bayesian Dose Adjustment (ISBA) platform estimates the MPA area under the curve (AUC)\n                      <jats:sub>0\u201312h<\/jats:sub>\n                      using 3 post-dose samples (20 minutes, 1 hour, 3 hours) and provides dose recommendations to target an AUC\n                      <jats:sub>0\u201312h<\/jats:sub>\n                      of 30\u201360 mg\u00b7h\/L. The aim of this study was to describe the MPA AUC\n                      <jats:sub>0\u201312h<\/jats:sub>\n                      and assess the impact of ISBA-guided dose adjustments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>MPA concentrations were measured at each visit, and AUCs were estimated in real time during routine clinical follow-up. All data collected from liver-transplant recipients aged \u226518 years from October 2005 to May 2020 were retrospectively analyzed. Dosing recommendations were adjusted proportionally to reach the AUC target of 45 mg.h\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 3632 requests involving 1872 patients were analyzed, making this the largest real-world cohort of this population reported to date. Among them, 658 patients benefited from at least 2 successive dose adjustments, allowing for a comparison between the results obtained without any prior use of the online platform and those obtained after the first visit (AUC of the second visit). At the first visit (before any dose recommendation) during the first year after transplantation, the median AUC\n                      <jats:sub>0\u201312h<\/jats:sub>\n                      (interquartile range) was 27 (16\u201339) mg\u00b7h\/L (n = 422). After dose adjustment recommendation, the median AUC\n                      <jats:sub>0\u201312h<\/jats:sub>\n                      increased significantly to 38 (30\u201349) mg\u00b7h\/L (n = 205,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The proportion of patients within the therapeutic target range (30\u201360 mg.h\/L) increased from 40% to 61% (+21%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Many patients were underexposed to MPA before dose adjustment. The ISBA recommendations significantly improved target attainment rates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001377","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T13:00:22Z","timestamp":1756386022000},"page":"314-321","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Large-Scale Real-World Monitoring of Mycophenolic Acid Exposure in Liver Transplantation: Impact of Bayesian Dose Adjustment"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5840-8904","authenticated-orcid":false,"given":"Marc","family":"Labriffe","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France;"},{"name":"Pharmacology & Transplantation, INSERM U1248, Universit\u00e9 de Limoges, Limoges, France;"},{"name":"F\u00e9d\u00e9ration Hospitalo-Universitaire Survival Optimization in Organ Transplantation (FHU SUPORT), Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Sayadi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France;"},{"name":"Pharmacology & Transplantation, INSERM U1248, Universit\u00e9 de Limoges, Limoges, France;"},{"name":"F\u00e9d\u00e9ration Hospitalo-Universitaire Survival Optimization in Organ Transplantation (FHU SUPORT), Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Micallef","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, INSERM U1248, Universit\u00e9 de Limoges, Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Saint-Marcoux","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France;"},{"name":"Pharmacology & Transplantation, INSERM U1248, Universit\u00e9 de Limoges, Limoges, France;"},{"name":"F\u00e9d\u00e9ration Hospitalo-Universitaire Survival Optimization in Organ Transplantation (FHU SUPORT), Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Destere","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d'Azur Medical Center, Department of Clinical Pharmacology, 06000 Nice, France; and"},{"name":"Universit\u00e9 C\u00f4te d'Azur, Inria, CNRS, Laboratoire J.A.-Dieudonn\u00e9, Maasai Team, Nice, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France;"},{"name":"Pharmacology & Transplantation, INSERM U1248, Universit\u00e9 de Limoges, Limoges, France;"},{"name":"F\u00e9d\u00e9ration Hospitalo-Universitaire Survival Optimization in Organ Transplantation (FHU SUPORT), Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Monchaud","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France;"},{"name":"Pharmacology & Transplantation, INSERM U1248, Universit\u00e9 de Limoges, Limoges, France;"},{"name":"F\u00e9d\u00e9ration Hospitalo-Universitaire Survival Optimization in Organ Transplantation (FHU SUPORT), Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"2 suppl","key":"R1-20260508","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","author":"Allison","year":"2005","journal-title":"Transplantation"},{"key":"R2-20260508","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International liver transplantation society consensus statement on immunosuppression in liver transplant recipients","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantation"},{"key":"R3-20260508","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/00007890-200102270-00005","article-title":"A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil","volume":"71","author":"Ringe","year":"2001","journal-title":"Transplantation"},{"key":"R4-20260508","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1600-6143.2011.03486.x","article-title":"Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study","volume":"11","author":"Boudjema","year":"2011","journal-title":"Am J Transpl."},{"key":"R5-20260508","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.transproceed.2005.03.145","article-title":"Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis","volume":"37","author":"Junge","year":"2005","journal-title":"Transpl Proc"},{"key":"R6-20260508","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/j.1600-6143.2012.04157.x","article-title":"Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials","volume":"12","author":"Goralczyk","year":"2012","journal-title":"Am J Transpl."},{"key":"R7-20260508","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1097\/TP.0000000000004209","article-title":"Recipient and center factors associated with immunosuppression practice beyond the first year after liver transplantation and impact on outcomes","volume":"106","author":"Bittermann","year":"2022","journal-title":"Transplantation"},{"key":"R9-20260508","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.phrs.2015.07.012","article-title":"Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients","volume":"99","author":"Woillard","year":"2015","journal-title":"Pharmacol Res."},{"key":"R10-20260508","doi-asserted-by":"crossref","first-page":"10715","DOI":"10.3748\/wjg.v20.i31.10715","article-title":"Clinical mycophenolic acid monitoring in liver transplant recipients","volume":"20","author":"Chen","year":"2014","journal-title":"World J Gastroenterol."},{"key":"R11-20260508","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s40262-019-00802-z","article-title":"Exposure-toxicity relationships of mycophenolic acid in adult kidney transplant patients","volume":"58","author":"Kiang","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"R12-20260508","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clinre.2019.12.001","article-title":"Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients","volume":"44","author":"Neuberger","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"R13-20260508","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/TP.0b013e3181ca7d84","article-title":"Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid","volume":"89","author":"van Gelder","year":"2010","journal-title":"Transplantation"},{"key":"R15-20260508","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/01.tp.0000232697.38021.9a","article-title":"Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature","volume":"82","author":"Arns","year":"2006","journal-title":"Transplantation"},{"key":"R16-20260508","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R17-20260508","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/FTD.0b013e31821633a6","article-title":"Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients","volume":"33","author":"Saint-Marcoux","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R18-20260508","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/FTD.0000000000001087","article-title":"Mycophenolate mofetil dose adjustment in pediatric kidney transplant recipients","volume":"45","author":"Labriffe","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R19-20260508","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.ftd.0000162231.90811.38","article-title":"Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods","volume":"27","author":"Pr\u00e9maud","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R20-20260508","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.phrs.2010.10.017","article-title":"Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches","volume":"63","author":"Pr\u00e9maud","year":"2011","journal-title":"Pharmacol Res."},{"key":"R21-20260508","doi-asserted-by":"crossref","first-page":"e0285734","DOI":"10.1371\/journal.pone.0285734","article-title":"Cumulative postoperative change in serum albumin levels and organ failure after living-donor liver transplantation: a retrospective cohort analysis","volume":"18","author":"Cho","year":"2023","journal-title":"PLoS One"},{"key":"R22-20260508","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/lt.21146","article-title":"Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil","volume":"13","author":"Jain","year":"2007","journal-title":"Liver Transplant"},{"key":"R23-20260508","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.tp.0000200307.79962.48","article-title":"Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil","volume":"81","author":"Brunet","year":"2006","journal-title":"Transplantation"},{"key":"R24-20260508","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1177\/0091270009358084","article-title":"Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period","volume":"50","author":"Benichou","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"R25-20260508","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/FTD.0000000000000052","article-title":"Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data","volume":"36","author":"Trkulja","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R26-20260508","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00007691-200110000-00003","article-title":"Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients","volume":"23","author":"Filler","year":"2001","journal-title":"Ther Drug Monit."},{"key":"R27-20260508","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/0091270004270145","article-title":"Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients","volume":"45","author":"Pisupati","year":"2005","journal-title":"J Clin Pharmacol."},{"key":"R28-20260508","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/ncpneph0159","article-title":"Patient factors explain variability in mycophenolic acid exposure","volume":"2","author":"Murdie","year":"2006","journal-title":"Nat Rev Nephrol."},{"key":"R29-20260508","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1681\/ASN.2005101070","article-title":"Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients","volume":"17","author":"van Hest","year":"2006","journal-title":"J Am Soc Nephrol."},{"key":"R30-20260508","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/jcph.745","article-title":"Pharmacokinetic variability of mycophenolic acid in pediatric and adult patients with hematopoietic stem cell transplantation","volume":"56","author":"Zhang","year":"2016","journal-title":"J Clin Pharmacol."},{"key":"R31-20260508","doi-asserted-by":"crossref","first-page":"859351","DOI":"10.3389\/fphar.2022.859351","article-title":"Population pharmacokinetics of mycophenolic acid in renal transplant patients: a comparison of the early and stable posttransplant stages","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol."},{"key":"R32-20260508","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/ki.2010.170","article-title":"Pharmacokinetics of mycophenolic acid in severe lupus nephritis","volume":"78","author":"Lertdumrongluk","year":"2010","journal-title":"Kidney Int."},{"key":"R33-20260508","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00007691-200002000-00005","article-title":"Pharmacokinetics of mycophenolic acid in renal insufficiency","volume":"22","author":"Meier-Kriesche","year":"2000","journal-title":"Ther Drug Monit."},{"key":"R34-20260508","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/00007890-199804270-00019","article-title":"Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure","volume":"65","author":"Kaplan","year":"1998","journal-title":"Transplantation"},{"key":"R35-20260508","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/j.1552-4604.1998.tb04424.x","article-title":"Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function","volume":"38","author":"Shaw","year":"1998","journal-title":"J Clin Pharmacol."},{"key":"R36-20260508","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1111\/j.1399-0012.2009.01166.x","article-title":"A clinical assessment of mycophenolate drug monitoring after liver transplantation","volume":"24","author":"Hwang","year":"2010","journal-title":"Clin Transpl."},{"key":"R37-20260508","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/FTD.0b013e31829b88f5","article-title":"Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus","volume":"35","author":"Pawinski","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R38-20260508","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/FTD.0b013e3182a37a1e","article-title":"Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation","volume":"36","author":"Langers","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R39-20260508","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/lt.20124","article-title":"Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range","volume":"10","author":"Tredger","year":"2004","journal-title":"Liver Transplant"},{"key":"R40-20260508","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.ftd.0000162231.90811.38","article-title":"Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods","volume":"27","author":"Pr\u00e9maud","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R41-20260508","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/FTD.0b013e3181aa776e","article-title":"Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses","volume":"31","author":"Kamar","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R42-20260508","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3350\/cmh.2014.20.3.291","article-title":"Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation","volume":"20","author":"Kim","year":"2014","journal-title":"Clin Mol Hepatol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:43:19Z","timestamp":1778578999000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001377","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"2025-04-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}